Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

2.

Pharmacological approaches to improve endothelial repair mechanisms.

Besler C, Doerries C, Giannotti G, Lüscher TF, Landmesser U.

Expert Rev Cardiovasc Ther. 2008 Sep;6(8):1071-82. doi: 10.1586/14779072.6.8.1071. Review.

PMID:
18793110
3.

Effects of statins on endothelium and endothelial progenitor cell recruitment.

Walter DH, Dimmeler S, Zeiher AM.

Semin Vasc Med. 2004 Nov;4(4):385-93. Review.

PMID:
15861319
4.

Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells.

Walter DH, Zeiher AM, Dimmeler S.

Coron Artery Dis. 2004 Aug;15(5):235-42. Review.

PMID:
15238818
5.

Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.

Rosenson RS.

Am J Cardiovasc Drugs. 2001;1(6):411-20. Review.

PMID:
14728000
6.

Influence of statin use on endothelial function: from bench to clinics.

Martínez-González J, Badimon L.

Curr Pharm Des. 2007;13(17):1771-86. Review.

PMID:
17584107
7.

Statins, nitric oxide and neovascularization.

Ma FX, Han ZC.

Cardiovasc Drug Rev. 2005 Winter;23(4):281-92. Review.

PMID:
16614729
8.

The role of endothelial progenitor cells and statins in endothelial function: a review.

Gómez-Cerezo JF, Pagán-Muñoz B, López-Rodríguez M, Estébanez-Muñoz M, Barbado-Hernández FJ.

Cardiovasc Hematol Agents Med Chem. 2007 Oct;5(4):265-72. Review.

PMID:
17979688
9.

Statin therapy and angiogenesis.

Skaletz-Rorowski A, Walsh K.

Curr Opin Lipidol. 2003 Dec;14(6):599-603. Review.

PMID:
14624137
10.

[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering].

Fujita R, Matsushima T.

Nihon Rinsho. 1999 Dec;57(12):2821-5. Review. Japanese.

PMID:
10638219
11.

Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?

Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N.

J Mol Cell Cardiol. 2012 Jan;52(1):83-92. doi: 10.1016/j.yjmcc.2011.09.014. Epub 2011 Sep 24. Review.

PMID:
21968328
12.

[Endothelial progenitor cells and atherosclerosis].

Hamed S, Roguin A.

Harefuah. 2006 May;145(5):358-61, 397. Review. Hebrew.

PMID:
16805218
13.

Role of endothelial dysfunction in atherosclerosis.

Davignon J, Ganz P.

Circulation. 2004 Jun 15;109(23 Suppl 1):III27-32. Review.

14.

Cardiac allograft vasculopathy and dysregulation of the NO synthase pathway.

Weis M, Cooke JP.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):567-75. Epub 2003 Mar 20. Review.

15.

The Role of Endothelial Progenitor Cells in Postnatal Vasculogenesis: Implications for Therapeutic Neovascularization and Wound Healing.

Balaji S, King A, Crombleholme TM, Keswani SG.

Adv Wound Care (New Rochelle). 2013 Jul;2(6):283-295. Review.

16.

Akt signaling and its role in postnatal neovascularization.

Ma FX, Han ZC.

Histol Histopathol. 2005 Jan;20(1):275-81. doi: 10.14670/HH-20.275. Review.

PMID:
15578445
17.

Circulating progenitor cells and scleroderma.

Gomer RH.

Curr Rheumatol Rep. 2008 Jul;10(3):183-8. Review.

18.

Clinical and therapeutical implications of EPC biology in atherosclerosis.

Werner N, Nickenig G.

J Cell Mol Med. 2006 Apr-Jun;10(2):318-32. Review.

19.

Spotlight on endothelial progenitor cell inhibitors: short review.

Thum T, Bauersachs J.

Vasc Med. 2005 Jul;10 Suppl 1:S59-64. Review.

PMID:
16444870
20.

Endothelial progenitor cells: a primer for vascular surgeons.

Magri D, Fancher TT, Fitzgerald TN, Muto A, Dardik A.

Vascular. 2007 Nov-Dec;15(6):384-94. Review.

PMID:
18053425

Supplemental Content

Support Center